Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-DFO-REGN5054 PET Imaging in Solid Malignancies Treated With Cemiplimab
NCT05259709Phase 1Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2023
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of 89Zr-DFO-REGN5054 in solid tumor (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Incidence and severity of treatment-emergent adverse events. Started Feb 2023; status: active, not recruiting.
02
Drugs
89Zr-DFO-REGN5054
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05259709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05259709.